<DOC>
	<DOCNO>NCT01245439</DOCNO>
	<brief_summary>This open-label study evaluate safety , tolerability efficacy RoActemra/Actemra ( tocilizumab ) patient moderate severe active rheumatoid arthritis ( RA ) background non-biologic DMARDs inadequate response current non-biologic DMARDs . Patients receive 8 mg/kg RoActemra/Actemra intravenous infusion every 24 week total 6 infusion . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Moderate severe active rheumatoid arthritis ( DAS28 &gt; /=3.2 ) &gt; /=6 month duration Body weight &lt; /=150 kg Patients one nonbiologic DMARDs stable dose period &gt; /=8 week prior study treatment Patients inadequate clinical response stable dose nonbiologic DMARD Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization Rheumatic autoimmune disease rheumatoid arthritis , include systemic lupus erythematosus , mixed connective tissue disease , scleroderma , polymyositis , significant systemic involvement secondary rheumatoid arthritis History current inflammatory joint disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>